WO2004019959A3 - Dna repair enzymes - Google Patents

Dna repair enzymes Download PDF

Info

Publication number
WO2004019959A3
WO2004019959A3 PCT/GB2003/003776 GB0303776W WO2004019959A3 WO 2004019959 A3 WO2004019959 A3 WO 2004019959A3 GB 0303776 W GB0303776 W GB 0303776W WO 2004019959 A3 WO2004019959 A3 WO 2004019959A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna repair
repair enzymes
hab2
hab1
activity
Prior art date
Application number
PCT/GB2003/003776
Other languages
French (fr)
Other versions
WO2004019959A9 (en
WO2004019959A2 (en
Inventor
Thomas Lindahl
Barbara Sedgwick
Sarah Trewick
Tod Duncan
Paul Bates
Original Assignee
Imp Cancer Res Technology
Thomas Lindahl
Barbara Sedgwick
Sarah Trewick
Tod Duncan
Paul Bates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220188A external-priority patent/GB0220188D0/en
Priority claimed from GB0224015A external-priority patent/GB0224015D0/en
Application filed by Imp Cancer Res Technology, Thomas Lindahl, Barbara Sedgwick, Sarah Trewick, Tod Duncan, Paul Bates filed Critical Imp Cancer Res Technology
Priority to AU2003263296A priority Critical patent/AU2003263296A1/en
Publication of WO2004019959A2 publication Critical patent/WO2004019959A2/en
Publication of WO2004019959A9 publication Critical patent/WO2004019959A9/en
Publication of WO2004019959A3 publication Critical patent/WO2004019959A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods of selection of agents and compositions for the treatment of proliferative diseases such as cancer. More specifically, the present invention relates to the methods of selecting compounds which modulate the activity of DNA repair enzymes HAB1 and HAB2 and their uses in the treatment of disorders, which would benefit from an increase or a decrease in HAB1 or HAB2 activity.
PCT/GB2003/003776 2002-08-30 2003-08-29 Dna repair enzymes WO2004019959A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263296A AU2003263296A1 (en) 2002-08-30 2003-08-29 Dna repair enzymes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0220188A GB0220188D0 (en) 2002-08-30 2002-08-30 DNA repair enzymes
GB0220188.7 2002-08-30
GB0224015.8 2002-10-15
GB0224015A GB0224015D0 (en) 2002-10-15 2002-10-15 DNA repair enzymes

Publications (3)

Publication Number Publication Date
WO2004019959A2 WO2004019959A2 (en) 2004-03-11
WO2004019959A9 WO2004019959A9 (en) 2004-04-22
WO2004019959A3 true WO2004019959A3 (en) 2005-01-06

Family

ID=31980001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003776 WO2004019959A2 (en) 2002-08-30 2003-08-29 Dna repair enzymes

Country Status (2)

Country Link
AU (1) AU2003263296A1 (en)
WO (1) WO2004019959A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006014106D1 (en) * 2005-03-14 2010-06-17 Link Genomics Inc METHOD FOR DIAGNOSIS OF PROSTATE CANCER
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012791A1 (en) * 1994-10-21 1996-05-02 Human Genome Sciences, Inc. Human abh

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012791A1 (en) * 1994-10-21 1996-05-02 Human Genome Sciences, Inc. Human abh

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARAVIND, L. AND KOONIN, E.V.: "The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases", GENOME BIOLOGY, vol. 2, no. 3, 19 February 2001 (2001-02-19), pages 0007.1 - 0007.8, XP002277811 *
DUNCAN, T. ET AL.: "Reversal of DNA alkylation damage by two human dioxygenases", PNAS, vol. 99, no. 26, 24 December 2002 (2002-12-24), pages 16660 - 16665, XP002277808 *
MARGISON, G.: "A new damage limitation exercise: ironing (Fe(II)) out minor DNA methylation lesions", DNA REPAIR, vol. 1, December 2002 (2002-12-01), pages 1057 - 1061, XP008029290 *
MARGISON, G.P. ET AL.: "Cloning of the E. coli O6-methylguanine and methylphosphotriester methyltransferase gene using a functional DNA repair assay", NUCLEIC ACID RESEARCH, vol. 13, no. 6, 1985, pages 1939 - 1952, XP002277809 *
PAL, O. ET AL.: "AlkB-mediated oxidative demethylation reverses DNA damage in Escherichia coli", NATURE, vol. 419, 12 September 2002 (2002-09-12), pages 178 - 182, XP002277810 *
TREWICK, S.C. ET AL.: "Oxidative demethylation by Escherichia coli AlkB directly reverts DNAbase damage", NATURE, vol. 419, 12 September 2002 (2002-09-12), pages 174 - 178, XP001180684 *

Also Published As

Publication number Publication date
AU2003263296A1 (en) 2004-03-19
AU2003263296A8 (en) 2004-03-19
WO2004019959A9 (en) 2004-04-22
WO2004019959A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
WO2004048551A3 (en) Target for therapy of cognitive impairment
WO2006113432A3 (en) Compounds, compositions and methods
WO2003094839A8 (en) Pyrimidinone compounds, compositions and methods
WO2004018058A3 (en) Compounds, compositions, and methods
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2006102283A3 (en) Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
WO2004009036A3 (en) Compounds compositions and methods
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2004006865A3 (en) Compounds, compositions, and methods
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004032840A3 (en) Compounds, compositions, and methods
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
WO2005046588A3 (en) Compounds, compositions, and methods
WO2004010956A3 (en) Antisense modulation of lar expression
WO2004034985A3 (en) Chemical compounds
WO2004100873A3 (en) Compounds, compositions, and methods
WO2004060878A3 (en) Inhibitors of phosphatases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/15-15/15, DRAWINGS, REPLACED BY CORRECT PAGES 1/19-19/19

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP